Fig. 3

Individual changes to disease biomarkers of MGUS and SMM from pre- to post-exercise training. (A) Individual changes to M-protein shown in the context of physiological variation to M-protein during monitoring of stable disease (CV 7.8%) [35] shown in grey. (B) Individual changes to M-protein shown in the context of historical disease activity measurements accessed from medical records. Intervention period shown in grey. (C) Individual changes to involved FLC shown in the context of physiological variation to involved FLC during monitoring of stable disease (CV 27.8%) [35] shown in grey. (D) Individual changes to involved FLC shown in the context of historical disease activity measurements accessed from medical records. Intervention period shown in grey. High baseline physical activity level defined as PAL ≥ 1.75. Low baseline physical activity level defined as PAL < 1.75. In panel B and D, three-year disease history was available and, as the frequency of disease monitoring between participants varied, time-points were arbitrarily assigned 0–12 in order to align the intervention period in all participants. In panel B and D, where M-protein and involved FLC are shown to decrease in one participant between timepoints 5–7, it should be noted that this participant received treatment for prostate cancer during that period. FLC = Free light chains